Naveen Pemmaraju, MD, discusses results from a phase I/II trial of tagraxofusp in patients with relapsed/refractory myelofibrosis, a disease with only one approved treatment option.
Recent Articles
Saad Usmani: Adding Daratumumab to Carfilzomib + Dexamethasone Extends PFS
Saad Usmani, MD, MBBS, shares findings from the CANDOR trial, in which the three-drug combination reduced the risk of disease progression or death by...
KTE-X19: A CAR T-Cell Option for Mantle Cell Lymphoma?
Ninety-three percent of patients with relapsed/refractory mantle cell lymphoma (MCL) responded to treatment with KTE-X19, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy,...
Clarithromycin Improves Responses But Fails to Prolong Survival in Newly Diagnosed Myeloma
Adding clarithromycin to lenalidomide plus dexamethasone improved the response rate in patients with multiple myeloma (MM), compared with lenalidomide and dexamethasone (Rd) alone. However,...
Bomedemstat Reduces Symptom Burden for Patients With Myelofibrosis
Bomedemstat improved symptoms in most patients with myelofibrosis, with no dose-limiting toxicities or progressions to acute myeloid leukemia, according to results from the first...
Mosunetuzumab Induces Durable Complete Remissions in Patients With B-Cell Non-Hodgkin Lymphoma
The bispecific monoclonal antibody mosunetuzumab, which targets CD3 and CD20, led to durable responses in patients with B-cell non-Hodgkin lymphoma (NHL), even in those...
Current Issue
December 2019, Volume 5, Issue 15
This issue examines the hidden costs of participating in clinical trials, explores the pediatric hematology/oncology workforce, and more.
